Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004
Guifang Shang
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorClive R. Seed
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorFei Wang
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorDongmei Nie
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorAlbert Farrugia
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorGuifang Shang
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorClive R. Seed
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorFei Wang
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorDongmei Nie
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorAlbert Farrugia
From the Blood and Tissue Unit, Therapeutic Goods Administration, Woden ACT, Australia; the Australian Red Cross Blood Service, Perth, Western Australia, Australia; and the Shenzhen Blood Center, Shenzhen, Guangdong, People's Republic of China.
Search for more papers by this authorAbstract
BACKGROUND: There are no current estimates of the residual risks of transmission by blood of hepatitis B virus (HBV) or hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in China. Such estimates are an essential prerequisite to monitoring and improving transfusion safety as well as supporting evidence based assessment of the value of implementing new screening interventions.
STUDY DESIGN AND METHODS: Viral screening data for donors from Shenzhen, China, for the period 2001 to 2004, were retrospectively analyzed. The data were applied to a published model to estimate the residual risk of transmitting HIV, HBV, and HCV by blood transfusion in Shenzhen, as well as to assess the residual risk reduction value of various new tests.
RESULTS: The point estimates for the combined 2003 and 2004 period calculate as 1 in 17,501 for HBV, 1 in 59,588 for HCV, and 1 in 903,498 for HIV. The predicted yield for improved hepatitis B surface antigen (HBsAg) assays, minipool (MP) nucleic acid testing (NAT), and individual-donation (ID) NAT was 6.9, 9.5, and 28.3 per million donations, respectively. The predicted yield for implementing a fourth-generation HCV (antigen-antibody) or MP NAT assay was 13.4 or 14.7 per million donations, respectively. For HIV, the predicted yield for implementing a fourth-generation HIV (antigen-antibody) or MP NAT assay was markedly smaller, 0.25 or 0.65 per million donations, respectively.
CONCLUSIONS: Relative to that reported for Western blood systems, the prevalence and the residual risk of HBV and HCV are high, whereas HIV is comparable. Pending a formal cost-effectiveness study for NAT, implementing improved HBsAg and combination HCV antibody-antigen assays in Shenzhen would markedly reduce the residual risk.
REFERENCES
- 1 Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005; 35: 592-8.
- 2 Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996-2003. Euro Surveill 2005; 10: 17-9.
- 3 Velati C, Fomiatti L, Baruffi L, et al. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005; 10: 12-4.
- 4 Pillonel J, Laperche S; Etablissement Francais du Sang. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005; 10: 5-8.
- 5 Chiavetta JA, Escobar M, Newman AM, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003; 169: 767-73.
- 6 Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez J, Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005; 10: 20-2.
- 7 Seed CR, Cheng A, Ismay SL, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42: 1365-72.
- 8 Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9.
- 9 Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002; 42: 966-72.
- 10 Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997; 11: 155-72.
- 11 Correll PK, Law MG, Seed CR, et al. Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sang 2001; 81: 6-11.
- 12 Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51: 31-46.
- 13 Hepatitis C [monograph on the Internet]. East Winsor (NJ): Medical Network, Inc. (d.b.a. HealthAtoZ.com); 2006 accessed December 31, 2006. http://www.hepatitis-central.com
- 14 Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-90.
- 15 Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
- 16 Laperche S, Le Marrec N, Girault A, et al. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43: 3877-83.
- 17 Kleinman S, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006; 35(Suppl): S34-S40.
- 18 Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-98.
- 19 Koppelman MH, Assal A, Chudy M, et al. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005; 45: 1258-66.
- 20 Shenzhen co-op medical scheme proves successful [monograph on the Internet]. Beijing: China Internet Information Center; 2006 accessed July 19, 2006. http://www.china.org.cn/english/2006/Feb/157626.htm
- 21 Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
- 22 Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol 2002; 67: 447-50.
- 23 Wang X, Ding D, Sun B. [Epidemiological feature of hepatitis B in Zaozhuang City, Shandong Province]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002; 16: 267-9.
- 24 Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003; 43: 192-201.
- 25 Song Y. Confident of a bright future. MCH Integration 1994; 39: 31.
- 26 Wang JT, Lee CZ, Chen PJ, et al. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 2002; 42: 1592-7.
- 27 Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005; 45: 1242-6.
- 28 SARS watch/chronology of government policy responses: public health measures 6 May 2003 [monograph on the Internet]. CITY: Asia Regional Information Center; 2003 accessed December 31, 2006. http://www.sarswatch.org
- 29 Coste J, Reesink HW, Engelfriet CP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005; 88: 289-303.
- 30 Busch MP, Tobler LH, Gerlich WH, et al. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003; 43: 1173-4.
- 31 Hyland C, Seed CR, Kiely P, et al. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests. Vox Sang 2003; 85: 1-8.
- 32 Shah DO, Chang CD, Jiang LX, et al. Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion 2003; 43: 1067-74.
- 33 Korelitz JJ, Busch MP, Kleinman SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997; 37: 634-40.
- 34 Fiebig EW, Heldebrant CM, Smith RI, et al. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr 2005; 39: 133-7.
- 35 Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002.
- 36 O'Sullivan BG, Gidding HF, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust. N Z J Pub Health 2004; 28: 212-6.
- 37 Liang XF, Chen YS, Wang XJ, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3 years old. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26: 655-8.
- 38 Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15(Suppl): E3-6.
- 39 Dore GJ, Law M, MacDonald M, et al. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171-84.
- 40 Nakano T, Lu L, He Y, et al. Population genetic history of hepatitis C virus 1b infection in China. J Gen Virol 2006; 87: 73-82.
- 41 Garten RJ, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-8.
- 42 Australian HIV surveillance report. Vol. 22, No. 1. Sydney: National Center in HIV Epidemiology and Clinical Research; 2006 Jan.
- 43 2005 Update on the HIV/AIDS Epidemic and Response in China. Ministry of Health, People's Republic of China, UNAIDS and WHO. 2006 Jan 24.
Citing Literature
